Springer Health+ IME

@SpringerIME · Global · joined 14 Mar 2016

Springer Health+ IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.

20 483Followers

2 762Following

1 987Posts total

5.6KViews on collected posts

Последние посты

Springer Health+ IME@SpringerIME9 Sep

Candidate selection and surgical considerations for presbyopia-correcting intraocular lenses: Start learning in these free, CME-accredited patient case modules, developed by Dr. Rahul Tonk and Dr. Caroline Watson: https://t.co/mgizp3bVu3 https://t.co/wiSJ0XmC9q

GIF

846 views · 1 likes · 1 reposts · 0 replies Open on X →

Springer Health+ IME@SpringerIME28 Aug

Help shape the discussion at #ESCCongress 2026 by sharing your experience of managing patients with heart failure and kidney impairment. Which unmet need in HF with kidney impairment management are you most hopeful new evidence will address? 2.4K views · 1 likes · 0 reposts · 0 replies Open on X →

Springer Health+ IME@SpringerIME27 Aug

Unpick regional disparities and patient perspectives on systemic lupus erythematosus in this free, CME-accredited video series, led by Prof. Martin Aringer and international experts in lupus care: https://t.co/iPorCybzGd https://t.co/H6mr5MCfa9

GIF

1K views · 2 likes · 0 reposts · 0 replies Open on X →

Springer Health+ IME@SpringerIME27 Aug

Help shape the discussion at #ESCCongress 2026 by sharing your experience of managing patients with heart failure and kidney impairment. A patient's eGFR dips after starting an SGLT2 inhibitor. What's your first move? 629 views · 0 likes · 0 reposts · 1 replies Open on X →

Springer Health+ IME@SpringerIME26 Aug

Hear from Dr. Larisa J. Geskin and fellow clinical experts in our free, CME-accredited webcast, where they explore the evolving therapeutic landscape of the tumor microenvironment in mycosis fungoides–type cutaneous T-cell lymphoma: https://t.co/fJT3j6NZhE https://t.co/bwT0sSEH8D

GIF

673 views · 0 likes · 0 reposts · 0 replies Open on X →

На фоне аккаунтов своего размера

5 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. обычный охват для своего размера, отклик слабее, чем у большинства.

Медианные просмотры846этот аккаунт924медиана для 10K–100K

Охват, %4.13%этот аккаунт3.62%медиана для 10K–100K

Вовлечённость, %0.16%этот аккаунт1.52%медиана для 10K–100K

Показатель	Этот аккаунт	Медиана для 10K–100K	Отношение
Медианные просмотры на пост	846	924	0.92×
Охват (просмотры ÷ подписчики)	4.13%	3.62%	1.14×
Вовлечённость	0.16%	1.52%	0.10×

Другие в этом диапазоне → Сравнить с другим аккаунтом → Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

67326 Aug

62927 Aug

2.4K28 Aug

8469 Sep

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.00%26 Aug

0.16%27 Aug

0.20%

0.04%28 Aug

0.24%9 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes66.7%4 in total

Reposts16.7%1 in total

Replies16.7%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.